These findings not only support the role of RB1 inactivation and EGFR downregulation in driving lineage plasticity but also illustrate that SCLC-transformed tumors acquire a distinct therapeutic profile no longer dependent on EGFR signaling. The gene discussed is RB1; the disease is small cell lung carcinoma.